These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
174 related articles for article (PubMed ID: 38597713)
1. Pembrolizumab plus chemotherapy for first-line treatment of advanced triple-negative breast cancer. Haiderali A; Huang M; Pan W; Akers KG; Maciel D; Frederickson AM Future Oncol; 2024; 20(22):1587-1600. PubMed ID: 38597713 [No Abstract] [Full Text] [Related]
2. Neoadjuvant immunotherapy and chemotherapy regimens for the treatment of high-risk, early-stage triple-negative breast cancer: a systematic review and network meta-analysis. Cortes J; Haiderali A; Huang M; Pan W; Schmid P; Akers KG; Park JE; Frederickson AM; Fasching PA; O'Shaughnessy J BMC Cancer; 2023 Aug; 23(1):792. PubMed ID: 37612624 [TBL] [Abstract][Full Text] [Related]
3. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Cortes J; Cescon DW; Rugo HS; Nowecki Z; Im SA; Yusof MM; Gallardo C; Lipatov O; Barrios CH; Holgado E; Iwata H; Masuda N; Otero MT; Gokmen E; Loi S; Guo Z; Zhao J; Aktan G; Karantza V; Schmid P; Lancet; 2020 Dec; 396(10265):1817-1828. PubMed ID: 33278935 [TBL] [Abstract][Full Text] [Related]
4. Atezolizumab and pembrolizumab in triple-negative breast cancer: a meta-analysis. Latif F; Bint Abdul Jabbar H; Malik H; Sadaf H; Sarfraz A; Sarfraz Z; Cherrez-Ojeda I Expert Rev Anticancer Ther; 2022 Feb; 22(2):229-235. PubMed ID: 34949142 [TBL] [Abstract][Full Text] [Related]
5. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Schmid P; Rugo HS; Adams S; Schneeweiss A; Barrios CH; Iwata H; Diéras V; Henschel V; Molinero L; Chui SY; Maiya V; Husain A; Winer EP; Loi S; Emens LA; Lancet Oncol; 2020 Jan; 21(1):44-59. PubMed ID: 31786121 [TBL] [Abstract][Full Text] [Related]
6. Current treatment landscape for patients with locally recurrent inoperable or metastatic triple-negative breast cancer: a systematic literature review. Li CH; Karantza V; Aktan G; Lala M Breast Cancer Res; 2019 Dec; 21(1):143. PubMed ID: 31842957 [TBL] [Abstract][Full Text] [Related]
7. Immune checkpoint inhibitors in first-line therapies of metastatic or early triple-negative breast cancer: a systematic review and network meta-analysis. Liang X; Chen X; Li H; Li Y Front Endocrinol (Lausanne); 2023; 14():1137464. PubMed ID: 37229447 [TBL] [Abstract][Full Text] [Related]
8. IMpassion132 double-blind randomised phase III trial of chemotherapy with or without atezolizumab for early relapsing unresectable locally advanced or metastatic triple-negative breast cancer. Dent R; André F; Gonçalves A; Martin M; Schmid P; Schütz F; Kümmel S; Swain SM; Bilici A; Loirat D; Villalobos Valencia R; Im SA; Park YH; De Laurentis M; Colleoni M; Guarneri V; Bianchini G; Li H; Kirchmayer Machackova Z; Mouta J; Deurloo R; Gan X; Fan M; Mani A; Swat A; Cortés J Ann Oncol; 2024 Jul; 35(7):630-642. PubMed ID: 38755096 [TBL] [Abstract][Full Text] [Related]
9. Effect of antitumor treatments on triple-negative breast cancer patients: A PRISMA-compliant network meta-analysis of randomized controlled trials. Tian Q; Du P; Li S; Bai Z; Yang Y; Zeng J Medicine (Baltimore); 2017 Nov; 96(45):e8389. PubMed ID: 29137021 [TBL] [Abstract][Full Text] [Related]
10. IMpassion132 Phase III trial: atezolizumab and chemotherapy in early relapsing metastatic triple-negative breast cancer. Cortés J; André F; Gonçalves A; Kümmel S; Martín M; Schmid P; Schuetz F; Swain SM; Easton V; Pollex E; Deurloo R; Dent R Future Oncol; 2019 Jun; 15(17):1951-1961. PubMed ID: 30977385 [TBL] [Abstract][Full Text] [Related]
11. Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial. Yardley DA; Brufsky A; Coleman RE; Conte PF; Cortes J; Glück S; Nabholtz JM; O'Shaughnessy J; Beck RM; Ko A; Renschler MF; Barton D; Harbeck N Trials; 2015 Dec; 16():575. PubMed ID: 26673577 [TBL] [Abstract][Full Text] [Related]
12. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer. Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176 [TBL] [Abstract][Full Text] [Related]
13. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer. Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104 [TBL] [Abstract][Full Text] [Related]
14. Pembrolizumab and atezolizumab in triple-negative breast cancer. Kwapisz D Cancer Immunol Immunother; 2021 Mar; 70(3):607-617. PubMed ID: 33015734 [TBL] [Abstract][Full Text] [Related]
15. Long-term survival after neoadjuvant therapy for triple-negative breast cancer under different treatment regimens: a systematic review and network meta-analysis. Liu Z; Li J; Zhao F; Ren D; Li Z; Chen Y; Huang S; Liu Z; Zhao Y; Wang M; Li H; Xu Z; Shen G; Zhao J BMC Cancer; 2024 Apr; 24(1):440. PubMed ID: 38594636 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of pembrolizumab based therapies in triple-negative breast cancer: A systematic review of clinical trials. Ali MA; Aiman W; Shah SS; Hussain M; Kashyap R Crit Rev Oncol Hematol; 2021 Jan; 157():103197. PubMed ID: 33309890 [TBL] [Abstract][Full Text] [Related]
17. Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522. Pusztai L; Denkert C; O'Shaughnessy J; Cortes J; Dent R; McArthur H; Kümmel S; Bergh J; Park YH; Hui R; Harbeck N; Takahashi M; Untch M; Fasching PA; Cardoso F; Zhu Y; Pan W; Tryfonidis K; Schmid P Ann Oncol; 2024 May; 35(5):429-436. PubMed ID: 38369015 [TBL] [Abstract][Full Text] [Related]
18. Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial. Winer EP; Lipatov O; Im SA; Goncalves A; Muñoz-Couselo E; Lee KS; Schmid P; Tamura K; Testa L; Witzel I; Ohtani S; Turner N; Zambelli S; Harbeck N; Andre F; Dent R; Zhou X; Karantza V; Mejia J; Cortes J; Lancet Oncol; 2021 Apr; 22(4):499-511. PubMed ID: 33676601 [TBL] [Abstract][Full Text] [Related]
20. Serial single-cell profiling analysis of metastatic TNBC during Nab-paclitaxel and pembrolizumab treatment. Deng J; Thennavan A; Shah S; Bagdatlioglu E; Klar N; Heguy A; Marier C; Meyn P; Zhang Y; Labbe K; Almonte C; Krogsgaard M; Perou CM; Wong KK; Adams S Breast Cancer Res Treat; 2021 Jan; 185(1):85-94. PubMed ID: 32949350 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]